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Abstract
Introduction:  The  treatment  of  inﬂammatory  bowel  disease  (IBD)  has  focussed  on  the  manage-
ment of  symptoms  but  is  becoming  more  resolute  on  changing  the  course  of  the  disease  and  its
complications  in  the  long-term.  In  order  to  minimize  the  development  of  complications  and  to
improve outcomes  for  these  patients  it  is  important  to  develop  other  strategies  to  manage  IBD
and to  optimize  current  clinical  practice.
Objective:  This  article  reports  the  main  consensus  statements  reached  during  the  Portuguese
National Meeting  on  improvement  of  disease  control  in  IBD,  on  optimization  of  corticosteroid
and immunosuppressive  use  in  Crohn’s  disease  and  on  best  practice  in  topics  of  current  interest
in Crohn’s  disease.
Methods:  An  International  Steering  Committee  selected  the  top  10  most  important  unanswered
practical  questions  on  the  use  of  conventional  therapy  in  Crohn’s  disease,  to  be  debated  and
analysed in  several  National  Meetings  of  different  countries.  In  each  country  a  National  Steering
Committee (NSC)  was  created  to  moderate  a  National  Meeting  during  which  several  expert
groups answered  the  selected  questions  in  light  of  their  clinical  practice.  Answers  were  classiﬁed
according  to  the  Oxford  levels  of  evidence.
Consensus:  A  general  consensus  was  obtained,  some  of  the  conclusions  were  as  follows.  It  is
important to  introduce  conventional  corticosteroids  in  moderate  to  severely  active  Crohn’s
disease of  any  localization  with  initial  duration  of  treatment  varying  according  to  patient’s
response; the  best  option  to  prevent  steroid-induced  side  effects  is  to  avoid  its  prolonged  or
repetitive  use  and  switching  appropriate  patients  to  immunosuppressive  therapy.  Initiation  of
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immunomodulators  early  in  the  disease  course  should  be  considered  for  patients  with  a  poor
prognosis and  optimal  safety  monitoring  was  discussed,  with  the  need  to  reassess  patients  at
appropriate  timepoints,  make  corticosteroid-free  remission  a  goal  and  treat  beyond  symptoms.
© 2012  Sociedade  Portuguesa  de  Gastrenterologia  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Consenso
Consenso  português  sobre  a  melhor  prática  clínica  para  tratamento  da  Doenc¸a
Inﬂamatória  do  Intestino:  resultados  da  reunião  IBD  Ahead  2010
Resumo
Introduc¸ão:  O  tratamento  da  Doenc¸a  Inﬂamatória  Intestinal  (DII)  tem-se  focado  no  controlo  dos
sintomas.  No  entanto,  nos  últimos  anos  tem-se  vindo  a  concentrar  mais  na  mudanc¸a  do  curso
da doenc¸a  e  das  suas  complicac¸ões  a  longo-prazo.  De  forma  a  minimizar  o  desenvolvimento
de complicac¸ões  e  melhorar  a  condic¸ão  dos  doentes,  torna-se  fundamental  desenvolver  outras
estratégias  para  controlo  da  DII  e  optimizar  a  prática  clínica  habitual.
Objectivos:  Este  artigo  relata  o  consenso  alcanc¸ado  por  um  grupo  de  peritos  durante  a  reunião
Nacional de  Peritos  relativamente  ao  controlo  da  doenc¸a  e  à  optimizac¸ão  do  uso  dos  corticos-
teroides e  imunossupressores  na  doenc¸a  de  Crohn.
Métodos:  Uma  Comissão  Cientíﬁca  Internacional  seleccionou  as  10  questões  práticas  mais
importantes  relativas  ao  uso  da  terapêutica  convencional  na  doenc¸a  de  Crohn,  aﬁm  das  mesmas
serem debatidas  e  analisadas  em  várias  Reuniões  Nacionais  de  diversos  países.  Em  cada  país  foi
constituída  uma  Comissão  Cientíﬁca  Nacional  para  moderar  a  Reunião  Nacional,  onde  vários  per-
itos nacionais  discutiram  e  responderam  às  questões  colocadas  de  acordo  com  a  prática  clínica.
As respostas  foram  classiﬁcadas  de  acordo  com  os  níveis  de  evidência  de  Oxford  e  avaliadas  de
acordo com  os  graus  de  evidência  de  Oxford.
Consenso: Foi  alcanc¸ado  um  consenso  geral.  Algumas  das  conclusões  encontradas  incluem:  a
importância  da  introduc¸ão  de  corticosteroides  na  doenc¸a  de  Crohn  activa  moderada  a  grave  de
qualquer  localizac¸ão;  a  durac¸ão  do  tratamento  com  corticosteroides,  nestes  casos,  deve  variar
de acordo  com  a  resposta  do  doente;  a  melhor  opc¸ão  para  prevenir  efeitos  secundários  induzidos
pelos corticosteroides  é  evitar  o  seu  uso  prolongado  e  repetitivo  e  a  passagem  apropriada
de alguns  doentes  para  terapêutica  imunossupressora.  A  administrac¸ão  de  imunomodeladores
numa fase  inicial  do  curso  da  doenc¸a  deve  ser  considerada  nos  doentes  com  mau  prognóstico.  Foi
também discutida  a  optimizac¸ão  da  monitorizac¸ão  da  seguranc¸a,  com  a  necessidade  de  reavaliar
os doentes  em  momentos  especíﬁcos  e  apropriados,  estipular  como  objectivo  a  remissão  livre
de corticosteroides  e  o  tratamento  para  além  dos  sintomas.
© 2012  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
a
t
c
e
C
a
s
o
i
c
a
i
a
t
cdireitos reservados.
Introduction
Inﬂammatory  bowel  disease  (IBD)  is  a  chronic  idiopathic
inﬂammatory  disorder  of  the  gastrointestinal  tract  which
includes  Crohn’s  disease  and  Ulcerative  Colitis.  Both
pathologies  are  characterized  by  intermittent  presence  of
symptoms  such  as  abdominal  pain,  diarrhea,  blood  in  the
stool,  and  systemic  symptoms.1
The  incidence  of  IBD  is  usually  higher  in  subjects  between
15  and  30  years  of  age.2 According  to  a  Portuguese  study
by  Azevedo  and  co-workers,  the  incidence  of  Crohn’s  dis-
ease  was  particularly  higher  in  the  age  stratum  between
17  and  39  years  and  the  prevalence  of  IBD  in  Portugal  in
2007  was  146  patients  per  100,000  subjects,  showing  an
increasing  trend  between  2003  (when  it  was  86  patients
per  100,000  individuals)  and  2007.3 Moreover,  the  incidence
of  IBD  is  considered  to  be  variable  in  different  regions
and  for  different  groups  of  population,  and  has  increased
in  recent  years.3,4 Several  studies  report  that  incidence  is
estimated  to  be  around  5--7  per  100,000  subjects/year  for
Crohn’s  disease  in  the  northern  hemisphere  countries,  such
d
e
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ts  the  United  States  of  America  and  northern  European  coun-
ries  and  about  0.1--4  per  100,000  subjects/year  in  southern
ountries.3,4 In  Portugal,  according  to  a  study  by  Shivananda
t  al.,  between  1991  and  1993,  the  estimated  incidence  of
rohn’s  disease  was  2.4  per  100,000  subjects  and  for  Ulcer-
tive  colitis  it  was  2.9  per  100,000.4
The  treatment  of  IBD  has  focussed  on  the  management  of
ymptoms  and,  in  recent  years,  has  become  more  resolute
n  changing  the  course  of  the  disease  and  its  complications
n  the  long-term.  In  fact,  the  probability  of  developing
omplications  requiring  hospitalization  and  surgery  is  high
nd  recurrence  after  surgery  is  also  common.5--7 Therefore,
n  order  to  minimize  the  development  of  these  complications
nd  to  improve  outcomes  for  these  patients,  it  is  important
o  develop  other  strategies  to  manage  IBD  and  to  optimize
urrent  clinical  practice.
With  the  main  objectives  of  discussing  ways  to  improve
isease  control  in  IBD,  to  outline  key  clinical  data  and
xperience  leading  to  optimization  of  corticosteroid
nd  immunosuppressive  use  in  Crohn’s  disease  and  to  debate
he  best  practice  in  topics  of  current  interest  in  Crohn’s
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isease,  several  National  Meetings  were  held  in  different
ountries.  This  article  reports  the  main  consensus  state-
ents  reached  in  the  Portuguese  National  Meeting.
ethodology
etween  July  and  August  2009,  26  key  unanswered  practical
uestions  on  the  use  of  conventional  therapy  in  Crohn’s  dis-
ase  were  identiﬁed  through  market  research.  During  the
ollowing  months  (September  and  October),  1400  partici-
ants  from  almost  30  countries  evaluated  those  questions
hrough  a  web-based  ranking,  giving  a  higher  score  for  those
onsidered  to  be  the  most  important.  Based  on  the  rank-
ng  results,  the  International  Steering  Committee  selected
he  top  10  questions  to  be  debated  and  analysed  in  several
ational  Meetings  of  different  countries.  National  Meetings
imed  at  providing  input  to  ascertain  national  perspectives
o  the  answers.
The  10  selected  questions  were:
1.  When  should  we  introduce  corticosteroids,  and  for
how  long?
2. What  is  the  best  dosing  strategy  for  the  use  of
corticosteroids  in  patients  with  Crohn’s  disease,  in
terms  of:  starting  and  maximum  doses,  duration,
dose  escalation/de-escalation  (when?  rate?),  formu-
lation,  avoiding  side-effects?
What  duration  of  corticosteroid  treatment  is  linked
to  the  occurrence  of  side  effects?
3. How  early  should  immunosuppressives  be  introduced
in  the  management  of  Crohn’s  disease  and  which  reg-
imen  should  be  used?
4. What  is  the  best  dosing  strategy  for  immunosup-
pressives  in  Crohn’s  disease,  in  terms  of:  starting
and  maximum  doses,  duration,  dose  escalation/de-
escalation  (when?  rate?),  which  immunosuppressive
ﬁrst?
5.  How  should  the  efﬁcacy  of  a  treatment  be  monitored
clinically  and  biologically?
What  is  the  deﬁnition  of  treatment  failure?  When
should  the  effect  of  treatment  be  evaluated?
Should  mucosal  healing  be  assessed?
6.  If  azathioprine  and  a  biologic  are  given  in  combina-
tion,  should  any  of  the  treatments  be  stopped?  Which
treatment  should  be  stopped  to  achieve  the  smallest
reduction  in  efﬁcacy?  When  should  that  treatment  be
stopped?
7.  If  the  immunosuppressive  does  not  work,  what  should
the  approach  be?  Add  steroids?  Increase  the  dosage?
Change  the  immunosuppressive?  Move  to  a  biologic?
8.  If  a  patient  experiences  ﬂare-ups  when  receiving
immunosuppressives  or  a  biologic,  should  corticos-
teroids  be  added?
9. What  are  the  risks  of  cancers  (all  kinds)  and  infections
associated  with  the  short-,  mid-  and  long-term  use  of
immunosuppressives  and  corticosteroids?
0. What  is  the  optimal  safety  monitoring  (clini-
cal,  laboratory,  radiological)  of  patients  receiving
immunosuppressives  or  corticosteroids?  How  often?
(F.  Magro  et  al.
After  identifying  the  10  questions,  a  specialist  company
as  contacted  to  perform  a  literature  search.  Based  on  the
iterature  search,  a  group  of  ﬁve  bibliographic  fellows  from
ifferent  countries,  analysed  the  results  of  the  search,  and
roduced  a  report  for  each  question  including  draft  answers
nd  supporting  information  with  references,  based  on  the
vidence  levels  (Table  1)  and  grades  of  recommendation
Table  2)  from  the  Oxford  Centre  for  Evidence.8 The  report
eveloped  by  the  bibliographic  fellows  was  reviewed  and
ach  of  the  draft  answers  was  consolidated  and  approved
y  a  group  of  project  mentors,  members  of  the  International
teering  Committee.
ethodology  of  the  National  Meeting
 National  Steering  Committee  (NSC)  was  created  including
ight  experts.  Their  main  objective  was  to  help  elaborate
he  agenda,  identify  additional  delegates  with  good  anti-
NF  therapy  experience,  develop/approve  materials,  and
oderate  the  National  Meeting  with  the  end  purpose  of
ontributing  to  the  development  of  its  outputs.
During  the  National  Meeting,  the  21  participants  split
nto  ﬁve  small  groups  (Group  1  with  ﬁve  members  and  the
emaining  ones  with  four  each)  to  review  two  answered
uestions  each.  The  small  groups  were  chaired  by  two
f  the  members  of  the  NSC  who  presented  the  proposed
raft  answers  and  moderated  the  discussion  until  the  group
ad  agreed  on  revised  wording  for  the  answers  to  their
elected  questions.  All  answers  were  classiﬁed  according  to
he  Oxford  levels  of  evidence  (Table  1)  and  graded  according
o  the  Oxford  grades  of  evidence  (Table  2).8
After  reaching  an  agreement,  all  participants  reconvened
o  present  their  selected  answers  to  the  entire  group,  fol-
owed  by  an  overall  group  vote  to  reach  a  consensus  for  each
nswer.  If  the  voting  did  not  achieve  an  agreement  after
he  initial  round,  participants  discussed  the  response  fur-
her  and  proposed  a  new  answer,  one  on  which  an  agreement
ould  be  reached.  If  there  was  no  consensus  after  two  votes,
here  was  no  further  discussion.  Participants  voted  accord-
ng  to  a  scale  from  1  (strong  disagreement)  to  9  (strong
greement).  Consensus  was  deﬁned  as  a score  of  7--9  by
75%  of  the  participants.
onsensus
able  3  shows  the  mean  scores  of  agreement  and  the  per-
entage  of  participants  who  agreed  with  the  answer  to  each
uestion.
Question  1.  When  should  we  introduce  corticosteroids
nd  for  how  long?
Draft  answer  modiﬁed  by  National  Meeting  Working
roup
1)  When  considered  as  a  treatment  option,  conventional
corticosteroids  should  be  introduced  in  moderate  to
severely  active  Crohn’s  disease  of  any  localization  (level
of  evidence:  1a;  grade  of  recommendation:  A).2)  However  budesonide  is  indicated  in  mild  active  ileocecal
and/or  right-sided  colonic  disease  and  is  preferred  to
conventional  corticosteroids  in  moderately  active  ileal
and  right-sided  colonic  Crohn’s  disease  (CDAI  up  to  300)
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Table  1  Levels  of  evidence  based  on  the  Oxford  Centre  for  Evidence.
Level Therapy/prevention/etiology/harm  Prognosis  Diagnosis
1a  SR  (with  homogeneitya)  of  RCTs  SR  (with  homogeneitya)  of
inception  cohort  studies;  CDRb
validated  in  different  populations
SR  (with  homogeneitya)  of  level  1
diagnostic  studies;  CDRb with  1b
studies  from  different  clinical  centres
1b Individual  RCT  (with  narrow
conﬁdence  intervalc)
Individual  inception  cohort  study
with  >80%  follow-up;  CDRb
validated  in  a  single  population
Validatingi cohort  study  with  goodh
reference  standards;  or  CDRb tested
within  one  clinical  centre
1c All or  noned All  or  none  case-series Absolute  SpPins  and  SnNoutsg
2a SR  (with  homogeneitya)  of  cohort
studies
SR  (with  homogeneitya)  of  either
retrospective  cohort  studies  or
untreated  control  groups  in  RCTs
SR  (with  homogeneitya)  of  level  >2
diagnostic  studies
2b Individual  cohort  study  (including  low
quality  RCT,  e.g.,  <80%  follow-up)
Retrospective  cohort  study  or
follow-up  of  untreated  control
patients  in  an  RCT;  derivation  of
CDRb or  validated  on  split-samplef
only
Exploratoryi cohort  study  with  goodh
reference  standards;  CDRb after
derivation,  or  validated  only  on
split-sample  or  databases
2c ‘‘Outcomes’’  research;  ecological
studies
‘‘Outcomes’’  research
3a SR  (with  homogeneitya)
of case-control  studies
SR  (with  homogeneitya)  of  3b
and  better  studies
3b Individual  case-control  study Non-consecutive  study;  or  without
consistently  applied  reference
standards
4 Case-series (and  poor  quality  cohort
and case-control  studiese)
Case-series  (and  poor  quality
prognostic  cohort  studiesj)
Case-control  study,  poor  or
non-independent  reference  standard
5 Expert  opinion  without  explicit
critical  appraisal,  or  based  on
physiology,  bench  research  or  ‘‘ﬁrst
principles’’
Expert  opinion  without  explicit
critical  appraisal,  or  based  on
physiology,  bench  research  or
‘‘ﬁrst  principles’’
Expert  opinion  without  explicit
critical  appraisal,  or  based  on
physiology,  bench  research  or  ‘‘ﬁrst
principles’’
a By homogeneity we mean a systematic review that is free of worrisome variations (heterogeneity) in the directions and degrees of
results between individual studies. Not all systematic reviews with statistically signiﬁcant heterogeneity need be worrisome, and not all
worrisome heterogeneity need be statistically signiﬁcant. As noted above, studies displaying worrisome heterogeneity should be tagged
with a ‘‘-’’ at the end of their designated level.
b Clinical Decision Rule. (These are algorithms or scoring systems that lead to a prognostic estimation or a diagnostic category.)
c See note above for advice on how to understand, rate and use trials or other studies with wide conﬁdence intervals.
d Met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx
became available, but none now die on it.
e By poor quality cohort study we mean one that failed to clearly deﬁne comparison groups and/or failed to measure exposures
and outcomes in the same (preferably blinded), objective way in both exposed and non-exposed individuals and/or failed to identify or
appropriately control known confounders and/or failed to carry out a sufﬁciently long and complete follow-up of patients. By poor quality
case-control study we mean one that failed to clearly deﬁne comparison groups and/or failed to measure exposures and outcomes in the
same (preferably blinded), objective way in both cases and controls and/or failed to identify or appropriately control known confounders.
f Split-sample validation is achieved by collecting all the information in a single tranche, then artiﬁcially dividing this into ‘‘derivation’’
and ‘‘validation’’ samples.
g An ‘‘Absolute SpPin’’ is a diagnostic ﬁnding whose Speciﬁcity is so high that a Positive result rules-in the diagnosis. An ‘‘Absolute
SnNout’’ is a diagnostic ﬁnding whose Sensitivity is so high that a Negative result rules-out the diagnosis.
h Good reference standards are independent of the test, and applied blindly or objectively to applied to all patients. Poor reference
standards are haphazardly applied, but still independent of the test. Use of a non-independent reference standard (where the ‘test’ is
included in the ‘reference’, or where the ‘testing’ affects the ‘reference’) implies a level 4 study.
i Validating studies test the quality of a speciﬁc diagnostic test, based on prior evidence. An exploratory study collects information
and trawls the data (e.g. using a regression analysis) to ﬁnd which factors are ‘signiﬁcant’.
j By poor quality prognostic cohort study we mean one in which sampling was biased in favour of patients who already had the target
outcome, or the measurement of outcomes was accomplished in <80% of study patients, or outcomes were determined in an unblinded,
tors.non-objective way, or there was no correction for confounding fac
due  to  its  safety  proﬁle  (level  of  evidence:  1a;  grade  of
recommendation:  A).
(3)  The  duration  of  initial  treatment  with  conventional  cor-
ticosteroids  at  full  dose  might  vary  depending  on  theresponse  of  the  patient.  There  is  no  clear  evidence  that
continuing  the  full  dose  beyond  weeks  1--3  inﬂuences
remission  rates  (level  of  evidence:  2b;  grade  of  recom-
mendation:  B).
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Table  2  Grades  of  recommendation  based  on  the  Oxford
Centre  for  Evidence.
Grades  of
recommendation
Description
A  Consistent  level  1  studies
B Consistent  level  2  or  3  studies  or
extrapolationsa from  level  1  studies
C Level  4  studies  or  extrapolationsa
from  level  2  or  3  studies
D Level  5  evidence  or  troublingly
inconsistent  or  inconclusive  studies
of any  level
a Extrapolations are where data are used in a situation that
u
i
d
a
t
G (
(has potentially clinically important differences than the original
study situation.
Question  2.  What  is  the  best  dosing  strategy  for  the
se  of  corticosteroids  in  patients  with  Crohn’s  disease,
n  terms  of:  starting  and  maximum  doses,  duration,
ose  escalation/de-escalation  (when?  rate?),  formulation,
voiding  side-effects?  What  duration  of  corticosteroid
reatment  is  linked  to  the  occurrence  of  side  effects?
Draft  answer  modiﬁed  by  National  Meeting  Working
roup
(1)  The  optimal  initial  dose  of  conventional  corticosteroids
in  Crohn’s  disease  ranges  from  40  to  60  mg/day  to
1  mg/kg  (level  of  evidence:  2b;  grade  of  recommen-
dation:  B).
(2) The  optimal  starting  dose  of  budesonide  is  9  mg/day
(level  of  evidence:  1b;  grade  of  recommendation:  A).
(3) The  duration  of  initial  treatment  with  conventional
corticosteroids  at  full  dose  might  vary  depending  on
the  response  of  the  patient.  There  is  no  clear  evidence
that  continuing  the  full  dose  beyond  weeks  1--3  inﬂu-
ences  remission  rates  (level  of  evidence:  2b;  grade  of
recommendation:  B).(4) Different  duration  regimens  of  budesonide  have  been
utilized,  with  most  using  a  full  dose  of  9  mg  for
Table  3  Mean  score  and  percentage  of  agreement  in  each
analysed  question.
Question  Mean  score
(1--9)
Percentage  for  consensus
achievement  (≥75%  voted
in  7--9  range)
1  8.44  96.50
2 8.37 92.58
3 8.56 100
4 7.96 92.60
5/Part  1 8.22  88.89
5/Part  2  7.93  85.19
6 8.48  96.30
7 8.48  100
8 8.67  100
9 8.44  96.30
10 8.41  92.59
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8--10  weeks  (level  of  evidence:  1a/2b;  grade  of  rec-
ommendation:  A/B).
(5)  A  tapering  regimen  of  conventional  corticosteroids
does  not  seem  to  inﬂuence  short-  or  long-term
remission  rates  (level  of  evidence:  2b;  grade  of  rec-
ommendation:  B).
(6)  No  data  are  available  to  allow  evaluation  of  any  bene-
ﬁt  of  intentional  escalation  of  steroid  dose  (i.e.  when
steroids  have  already  been  started  for  induction  of
remission)  (level  of  evidence:  1b/2b;  grade  of  recom-
mendation:  A/B).
(7) Neither  conventional  steroids  nor  budesonide  are
effective  in  maintenance  of  remission  (level  of  evi-
dence:  1a;  grade  of  recommendation:  A).
(8) In  corticosteroid-dependent  patients  with  quies-
cent  disease,  budesonide  may  facilitate  the  with-
drawal  of  conventional  corticosteroids,  minimizing
side-effects  before  the  delayed  beneﬁt  of  azathio-
prine/methotrexate  in  the  maintenance  of  remission
(level  of  evidence:  1b/5;  grade  of  recommendation:
A/D).
(9) No  data  are  available  on  the  efﬁcacy  of  different  con-
ventional  steroids.  Different  oral  formulations  are  used
for  induction  of  remission  in  different  studies  with-
out  substantial  differences  in  remission  rates  (level  of
evidence:  1b/2b;  grade  of  recommendation:  A/B).
10) IV  Corticosteroids  are  an  option  for  patients  failing
to  respond  to  oral  corticosteroids  (level  of  evidence:
3b/5;  grade  of  recommendation:  B/D).
11) Corticosteroids  have  been  shown  to  increase  the  risk
of  serious  and  opportunistic  infections,  both  indepen-
dently  and  in  combination  with  immunosuppressive
and  biologic  agents.  Thus,  the  best  option  to  pre-
vent  steroid-induced  side  effects  is  to  avoid  prolonged
or  repetitive  use  and  to  switch  appropriate  patients
to  immunosuppressive  therapy.  To  prevent  steroid-
induced  loss  of  bone  mineral  density,  calcium  and
vitamin  D  supplements  should  be  provided.  How-
ever,  not  all  steroid-induced  side  effects  are  dose-  or
time-dependent  (level  of  evidence:  2b;  grade  of  rec-
ommendation:  B).
Question  3.  How  early  should  immunosuppressives  be
ntroduced  in  the  management  of  Crohn’s  disease  and
hich  regimen  should  be  used?
Draft  answer  modiﬁed  by  National  Meeting  Working
roup
1)  Initiation  of  immunosuppressives  early  in  the  disease
course  (at  ﬁrst  ﬂare  needing  steroids)  should  be  consid-
ered  (level  of  evidence:  1b;  grade  of  recommendation:
A)
2)  This  is  particularly  relevant  in  patients  at  high  risk
of  complicated  disease:  perianal  disease,  age  below
40,  extensive  disease  and  structuring  or  penetrating
behaviour  at  diagnosis  (level  of  evidence:  3b;  grade  of
recommendation:  B).
3)  Immunosuppressives  are  indicated  in
immunosuppressive-naïve  patients  starting  systemic
steroids  or  inﬂiximab  in  order  to  achieve  steroid-sparing
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effects  or  added  beneﬁt  (level  of  evidence:  1b;  grade
of  recommendation:  A).
(4) Purine  analogues  are  effective  in  post-operative  prophy-
laxis  immediately  after  surgical  resection  of  ileocolonic
disease  (level  of  evidence:  1a;  grade  of  recommenda-
tion:  A).
(5)  Evidence  for  the  use  of  purine  analogues  as  ﬁrst-line
therapy  in  perianal  ﬁstulating  Crohn’s  disease  is  limited
(level  of  evidence:  2;  grade  of  recommendation:  B).
Question  4.  What  is  the  best  dosing  strategy  for
immunosuppressives  in  Crohn’s  disease,  in  terms  of:  start-
ing  and  maximum  doses,  duration,  dose  escalation/de-
escalation  (when?  rate?),  which  immunosuppressive  ﬁrst?
Draft  answer  modiﬁed  by  National  Meeting  Working
Group
(1) The  most  effective  doses  appear  to  be  2.0--3.0  mg/kg  for
azathioprine  and  1.0--1.5  mg/kg  for  6-mercaptopurine
administered  orally,  based  on  reported  clinical  trials.
There  is  no  evidence  to  support  dose  de-escalation
(level  of  evidence:  1a;  grade  of  recommendation:  A).
(2) For  methotrexate,  the  dosing  strategy  should  be  25  mg
per  week  intramuscularly  for  16  weeks  as  induction,  and
15  mg  per  week  in  maintenance.  There  is  no  evidence  to
support  further  dose  de-escalation  (level  of  evidence:
1b;  grade  of  recommendation:  A).
(3) Azathioprine  is  recommended  as  the  ﬁrst-line  immuno-
suppressive,  as  higher  response  rates  were  observed
with  it  compared  with  6-mercaptopurine  and  evidence
for  the  use  of  methotrexate  is  scarce  (level  of  evidence:
5;  grade  of  recommendation:  D).
(4)  Recommended  initial  dose  strategies  are  either  a grad-
ual  dose  increase  starting  with  50  mg  of  azathioprine
(25  mg  of  6-mercaptopurine)  or  full  dose  therapy  (level
of  evidence:  1b;  grade  of  recommendation:  A).
(5)  In  case  of  full  dose  therapy,  prior  determination  of
thiopurine  methyltransferase  activity/genotype  should
be  done  whenever  available  (level  of  evidence:  5;  grade
of  recommendation:  D).
(6)  Azathioprine  or  6-mercaptopurine  treatment  should  be
maintained  for  several  years  due  to  a  high  relapse  rate
in  patients  with  Crohn’s  disease  when  these  drugs  are
discontinued  (level  of  evidence:  1b;  grade  of  recommen-
dation:  A).
Question  5/Part  1.  How  should  the  efﬁcacy  of  a  treat-
ment  be  monitored  clinically  and  biologically?  What  is  the
deﬁnition  of  treatment  failure?  When  should  the  effect  of
treatment  be  evaluated?
Draft  answer  modiﬁed  by  National  Meeting  Working
Group
(1)  Remission  of  signs  and  symptoms  is  the  most  widely  clin-
ically  accepted  endpoint  for  treatment  efﬁcacy.  The
Crohn’s  Disease  Activity  Index  and  Harvey  Bradshaw
Index  are  accepted  tools  for  quantiﬁcation  of  efﬁcacy
in  clinical  trials,  the  latter  is  simple  enough  to  allow  its
use  in  clinical  practice  (level  of  evidence:  5;  grade  of
recommendation:  D).
(2)  Indirect  biomarkers  of  treatment  efﬁcacy  include:of  inﬂammatory  bowel  disease  195
3)  Elevated  serum  C-reactive  protein  (correlates  well  with
disease  relapse  except  for  upper  GI  tract  disease  (level
of  evidence:  2b/4;  grade  of  recommendation:  B/C).
4) Faecal  calprotectin  below  the  cut-off  level  of  the  indi-
vidual  test  (predictive  of  mucosal  healing  and  reduced
relapse  in  Crohn’s  disease)  (level  of  evidence:  4;  grade
of  recommendation:  C).
5)  The  use  of  azathioprine  metabolites  and  trough  inﬂix-
imab  or  adalimumab  levels  may  help  management
decisions  and  more  accurately  identify  non-responders.
For  azathioprine  users,  metabolites  are  helpful  in  non-
responders.  For  biologics,  trough  levels  cannot  be
recommended  in  clinical  practice  at  this  time  (level  of
evidence:  5;  grade  of  recommendation:  D).
6) For  treatment  with  thiopurines  or  methotrexate,  clin-
ical  response  should  be  assessed  after  3  months.
However,  if  mucosal  healing  is  to  be  assessed,  this  should
be  carried  out  at  6-12  months  and  at  2  years  (level  of
evidence:  4/1b;  grade  of  recommendation:  C/A).
7) For  treatment  with  biological  agents,  clinical  response
should  be  assessed  between  6  and  14  weeks  (level  of
evidence:  1a;  grade  of  recommendation:  A).
8) Patients  failing  to  respond  symptomatically  after  ade-
quate  therapy  with  thiopurines  or  methotrexate  for  at
least  3--6  months  or  with  a  biologic  for  at  least  6--
14  weeks  constitute  a  treatment  failure  (level  of  evi-
dence:  2b  -- thiopurines;  grade  of  recommendation:  B).
9) Considering  immunossupressors  and/or  biologics,  treat-
ment  failure  should  also  include  absence  of  endoscopic
improvement  (level  of  evidence:  1b  -- biologics;  grade
of  recommendation:  A).
Question  5/Part  2.  Should  mucosal  healing  be  assessed?
Draft  answer  modiﬁed  by  National  Meeting  Working
roup
1)  Achievement  of  mucosal  healing  in  Crohn’s  disease  leads
to  prolonged  steroid-free  remission,  fewer  abdominal
surgeries  and  may  reduce  hospitalizations  (Level  of  Evi-
dence:  2b  --  remission;  Grade  of  recommendation:  B);
(Level  of  Evidence:  4  --  surgery;  Grade  of  recommenda-
tion:  C);  (level  of  evidence:  2b  --  hospitalization;  grade
of  recommendation:  B).
2)  There  is  good  evidence  to  suggest  that  azathioprine,
inﬂiximab  and  adalimumab  are  effective  at  healing  the
colonic  mucosa  completely  (level  of  evidence:  2b;  grade
of  recommendation:  B).
3)  Early  combined  immunosuppressive  therapy  in  moder-
ately  active  Crohn’s  disease  is  superior  to  standard
therapy  in  establishing  mucosal  healing,  mainly  in  naive
patients  for  both  drugs  (level  of  evidence:  1b;  grade  of
recommendation:  A).
4)  Methotrexate  and  certolizumab  are  also  capable  of
mucosal  healing,  although  the  evidence  base  is  less  ﬁrm
(level  of  Evidence:  4  --  methotrexate;  grade  of  recom-
mendation:  C);  (level  of  evidence:  3b  --  certolizumab;
grade  of  recommendation:  B);
5)  Although  further  studies  are  needed,  monitoring  of
endoscopic  response  to  biologics  and/or  immunossu-
pressors  should  be  recommended  within  2  years  (level
of  evidence:  1b/2b;  grade  of  recommendation:  A/B).
Non-invasive  markers  such  as  C-reactive  protein  and  in
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particular  faecal  calprotectin  may  become  an  alterna-
tive  to  endoscopy  for  the  assessment  of  mucosal  healing
(level  of  evidence:  4;  grade  of  recommendation:  C).
Question  6.  If  azathioprine  and  a  biologic  are  given  in
ombination,  should  any  of  the  treatments  be  stopped?
hich  treatment  should  be  stopped  to  achieve  the  small-
st  reduction  in  efﬁcacy?  When  should  that  treatment  be
topped?
Draft  answer  modiﬁed  by  National  Meeting  Working
roup
1)  In  patients  with  moderately  active  Crohn’s  disease  naïve
to  immunosuppressive  therapy,  the  combination  of  an
immunosuppressive  with  inﬂiximab  improves  rates  of
steroid-free  remission  up  to  1  year  after  initiation
of  therapy  (level  of  evidence:  1b;  grade  of  recommen-
dation:  A).
2) In  patients  refractory  to  immunosuppressive  therapy,
continuation  of  that  therapy  in  conjunction  with  a  bio-
logic  offers  no  clinical  beneﬁt  up  to  2  years  (level  of
evidence:  1b;  grade  of  recommendation:  A).
3)  If  the  immunosuppressive  is  to  be  continued  in  conjunc-
tion  with  a  biologic,  then  the  immunosuppressive  may
be  discontinued  after  6  months.  However,  this  decision
must  be  individualized  (level  of  evidence:  4;  grade  of
recommendation:  C).
4)  There  is  no  evidence  that  immunossupressor  and/or
inﬂiximab  use  are  independent  predictors  for  serious
infections  (level  of  evidence:  2b;  grade  of  recommen-
dation:  B)
5)  Use  of  azathioprine  is  not  associated  with  increased  risk
of  cancer  except  for  lymphoma  (level  of  evidence:  3b;
grade  of  recommendation:  C).
6)  Up  to  now  there  is  insufﬁcient  data  to  know  whether
use  of  biologics  alone  is  associated  with  increased  risk
of  lymphoma  (level  of  evidence:  2;  grade  of  recommen-
dation:  B).
7)  There  is  a  small  potential  risk  of  hepatosplenic  T-cell
lymphoma  in  young  males  with  Crohn’s  disease  being
treated  with  a  combination  of  azathioprine  and  inﬂix-
imab  (level  of  evidence:  4;  grade  of  recommendation:
C).
Question  7.  If  the  immunosuppressive  does  not  work,
hat  should  the  approach  be?  Increase  the  dosage?  Add
teroids?  Change  the  immunosuppressive?  Move  to  a  bio-
ogic?
Draft  answer  modiﬁed  by  National  Meeting  Working
roup
1)  Optimization  of  thiopurine  therapy  should  always  be
considered  if  underdosing  is  suspected  on  a  dose/weight
basis  (level  of  evidence:  1a;  grade  of  recommendation:
A).
2)  Anti-TNF  agents  should  be  the  ﬁrst  consideration  in
patients  who  did  not  respond  to  immunosuppressives  or
lost  response  (level  of  evidence:  1a;  grade  of  recom-
mendation:  A).
3)  Adding  steroids  may  be  necessary  in  the  short  term,  but
they  are  not  recommended  for  long-term  use  (patients
(F.  Magro  et  al.
should  be  weaned  off  steroids)  (level  of  evidence:  4;
grade  of  recommendation:  C).
4)  In  case  of  intolerance  or  side  effects  to  azathioprine
or  6-mercaptopurine,  other  immunosuppressives  may  be
considered.  Alternative  immunosuppressives  include:
methotrexate  (level  of  evidence:  1b/4;  grade  of  rec-
ommendation:  A/C)  tacrolimus  and  6-thioguanine  (in
limited  settings  only)  (level  of  evidence:  4;  grade  of
recommendation:  C).
Question  8.  If  a  patient  experiences  ﬂare-ups  when
eceiving  immunosuppressives  or  a  biologic,  should  corti-
osteroids  be  added?
Draft  answer  modiﬁed  by  National  Meeting  Working
roup
1)  Patients  failing  immunosuppressive  therapy  can  be
started  on  corticosteroids  to  help  induce  remission  when
transitioning  to  another  immunosuppressive  (level  of
evidence:  1b;  grade  of  recommendation:  A).
2) Biologics  should  be  considered  as  both  induction  and
maintenance  agents,  and  transition  with  corticosteroids
may  not  be  necessary  (level  of  evidence:  1b;  grade  of
recommendation:  A).
3) When  started,  corticosteroid  dose  should  be  rapidly
tapered  over  a  period  of  weeks  to  avoid  long-term  expo-
sure  (level  of  evidence:3;  grade  of  recommendation:
B).
4) Given  their  signiﬁcant  side-effect  proﬁle,  use  of  corti-
costeroids  should  be  limited  or  avoided  where  possible
(level  of  evidence:  2b;  grade  of  recommendation:  B).
5)  If  a  patient  loses  response  to  a  biologic,  optimization
of  therapy  should  be  considered  (level  of  evidence:  1b;
grade  of  recommendation:  A).
Question  9.  What  are  the  risks  of  cancers  (all  kinds)  and
nfections  associated  with  the  short-,  mid-  and  long-term
se  of  immunosuppressives  and  corticosteroids?
Draft  answer  modiﬁed  by  National  Meeting  Working
roup
1)  Although  the  overall  cancer  risk  does  not  seem  to  be
increased  in  patients  on  steroids  or  immunosuppres-
sives,  thiopurines  increase  the  risk  of  lymphoprolifer-
ative  disorders  and  non-melanoma  skin  cancer  in  IBD
patients  (level  of  evidence:  2b;  grade  of  recommenda-
tion:  B).
2) The  concomitant  use  of  immunosuppressive  agents  and
biologics  should  be  minimized,  especially  in  adolescents
and  young  male  adults  (level  of  evidence:  4;  grade  of
recommendation:  C).
3) Steroids  and  immunosuppressives  are  associated  with  an
increased  risk  of  infection  (level  of  evidence:  2b;  grade
of  recommendation:  B).
4) The  risk  of  infection  in  patients  with  IBD  increases  with
the  association  of  corticosteroids  and  thiopurines  and
biologics  (level  of  evidence:  3b;  grade  of  recommenda-
tion:  B).
5) The  concomitant  use  of  corticosteroids  and  thiopurines
or  corticosteroids  and  biologics  also  increases  the  risk
(level  of  evidence:  3b;  grade  of  recommendation:  B).
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Question  10.  What  is  the  optimal  safety  monitoring
(clinical,  laboratory,  radiological)  of  patients  receiving
immunosuppressives  or  corticosteroids?  How  often?
Draft  answer  modiﬁed  by  National  Meeting  Working
Group
(1)  Immunosuppressive  therapy  is  associated  with  myelo-
suppression.  Patients  with  low  thiopurine  methyl-
transferase  (TPMT)  activity  are  at  increased  risk  of
developing  severe  myelosuppression.  However,  73%
of  patients  with  severe  bone  marrow  suppression  do
not  carry  a  TPMT  mutation  (level  of  evidence:  3b/5;
grade  of  recommendation:  B/D).
(2)  As  TPMT  analysis  may  predict  90%  of  life-threatening
episodes  and  60%  of  severe  and  moderate  episodes
of  neutropenia,  measuring  TPMT  activity  prior  to
starting  thiopurines  is  a  way  to  identify  patients
at  high  risk  of  severe  haematological  complications
(level  of  evidence:  2a;  grade  of  recommendation:
B).
(3) It  remains  to  be  established  whether  measuring  TPMT
activity/genotype  is  a  cost-effective  strategy  (level  of
evidence:  5;  grade  of  recommendation:  D).
(4) Patients  receiving  thiopurines  need  regular  monitor-
ing  of  full  blood  count  before  and  within  4  weeks  of
starting  therapy  and  then  every  3  months  with  liver
tests  (level  of  evidence:  5;  grade  of  recommendation:
D).
(5)  In  patients  receiving  methotrexate,  measurement  of
full  blood  count  and  liver  function  tests  are  advisable
before  and  within  4  weeks  of  starting  therapy,  then
monthly  to  every  3  months  (level  of  evidence:  5;  grade
of  recommendation:  D).
(6)  The  EBV  status  of  the  patients  submitted  to  immuno-
suppression  should  be  assessed  (level  of  evidence:  5;
grade  of  recommendation:  D).
(7)  Nodular  regenerative  hyperplasia  is  a  rare  but  poten-
tially  severe  complication  of  azathioprine  in  patients
with  IBD  (level  of  evidence:  5;  grade  of  recommenda-
tion:  D).
(8)  Skin  cancer  screening  programs  should  be  performed
according  to  a  regular  schedule  (level  of  evidence:  5;
grade  of  recommendation:  D).
(9) Clinical  monitoring  of  patients  receiving  doses  of
steroids  is  recommended,  and  doses  should  be  tapered
(level  of  evidence:  not  applicable).
(10) In  patients  with  more  than  3  months  or  recurrent
courses  of  steroids  DXA  should  be  ordered  (level  of
evidence:  5;  grade  of  recommendation:  D).
Conclusions
The  main  conclusions  which  can  be  drawn  after  this  meeting
include:  the  importance  of  introducing  conventional  corti-
costeroids  in  moderate  to  severely  active  Crohn’s  disease  of
any  localization  with  an  initial  duration  of  treatment  varying
according  to  patient’s  response;  in  mildly  active  ileocecal
and/or  right-sided  colonic  disease  the  use  of  budesonide  is
recommended,  this  being  preferred  to  conventional  corti-
costeroids  due  to  its  safety  proﬁle.  Furthermore,  neither
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onventional  steroids  nor  budesonide  are  effective  for  main-
enance  of  remission.
Corticosteroids  have  been  shown  to  increase  the  risk
f  serious  and  opportunistic  infections,  both  indepen-
ently  and  in  combination  with  immunosuppressive  and
iologic  agents.  Thus,  the  best  option  to  prevent  steroid-
nduced  side  effects  is  to  avoid  prolonged  or  repetitive  use
nd  to  switch  appropriate  patients  to  immunosuppressive
herapy.  Furthermore,  the  administration  of  immuno-
uppressives  should  be  considered  early  in  the  disease
ourse,  particularly  in  patients  at  high  risk  of  complicated
isease.
For  IBD  the  most  important  and,  in  clinical  terms,  most
idely  accepted  endpoint  for  treatment  efﬁcacy  is  the
emission  of  disease  signs  and  symptoms.  Therefore,  all
atients  failing  to  respond  symptomatically  after  adequate
herapy  with  thiopurines  or  methotrexate  for  at  least  3--
onths  or  with  a  biologic  for  at  least  6--4  weeks  are
onsidered  a  treatment  failure.  With  regards  to  immunos-
upressors  and/or  biologics,  treatment  failure  should  also
nclude  absence  of  endoscopic  improvement.
The  evidence  that  suggests  that  methotrexate  is  capa-
le  of  mucosal  healing  is  not  as  robust  as  the  evidence
upporting  the  effective  and  complete  healing  of  the
ucosa  achieved  with  azathioprine,  inﬂiximab  and  adali-
umab.  Evidence  also  suggests  that  the  early  combination
f  immunosuppressive  therapy  in  moderately  active  Crohn’s
isease  is  superior  to  standard  therapy  in  establishing
ucosal  healing,  mainly  in  patients  who  are  naïve  to  both
rugs.  The  use  of  non-invasive  markers  such  as  C-reactive
rotein  and  in  particular  faecal  calprotectin  may  become  a
omplementary  means  to  endoscopy  for  the  assessment  of
ucosal  healing.
Concerning  the  risk  of  cancer,  there  is  evidence  sup-
orting  an  increased  risk  of  developing  lymphoproliferative
isorders  and  non-elanoma  skin  cancer  in  IBD  patients
reated  with  azathioprine.  Steroids  and  immunosuppressives
re  associated  with  an  increased  risk  of  infection.  The  com-
ination  treatment,  immunomodulators  and  corticosteroids
r  biologics,  increases  this  risk.
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